Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation

BACKGROUND: The major barriers to mesenchymal stem cell (MSC) therapy in rheumatoid arthritis (RA) are a low extent of tissue regeneration and insufficient immunomodulation after cell transplantation. In addition, the role of C-X-C chemokine receptor type 7 (CXCR7) and its mechanism of action in MSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Sung-Tai, Huang, Yen-Chih, Chiang, Jung-Ying, Lin, Chia-Ching, Lin, Yu-Jung, Shyu, Woei-Cherng, Chen, Hui-Chen, Hsieh, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164772/
https://www.ncbi.nlm.nih.gov/pubmed/34051857
http://dx.doi.org/10.1186/s13287-021-02402-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164772/
https://www.ncbi.nlm.nih.gov/pubmed/34051857
http://dx.doi.org/10.1186/s13287-021-02402-w

Ejemplares similares